Key result
Over 24 months, GLP-1RA therapy was associated with lower all-cause mortality and fewer heart failure hospitalizations than bariatric surgery in 1,910 adults with hypertrophic cardiomyopathy.
Why the study?
Does GLP-1RA therapy improve cardiovascular outcomes compared to bariatric surgery in adults with hypertrophic cardiomyopathy and obesity?
Does GLP-1RA therapy improve cardiovascular outcomes compared to bariatric surgery in adults with hypertrophic cardiomyopathy and obesity?
Answers are grounded in this paper and cite their sources.
In patients with hypertrophic cardiomyopathy and obesity, GLP-1 receptor agonists may provide cardiovascular benefits that extend beyond weight loss when compared to bariatric surgery.
This editorial refers to ‘Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis’, by A.K. Mahmoud et al. https://doi.org/10.1093/ehjqcco/qcag051 Obesity is not a passive bystander in hypertrophic cardiomyopathy (HCM). It is a clinically relevant disease modifier associated with greater symptom burden, more adverse remodelling, and worse long-term outcomes.1–3 Accordingly, weight management has become part of contemporary HCM care rather than a generic lifestyle afterthought.3 Yet, a central question remains unresolved: In patients with HCM and obesity, are all weight-loss strategies biologically equivalent, or might some approaches influence cardiovascular outcomes through mechanisms that extend beyond the number on the scale? In this issue of the European Heart Journal-Quality of Care and Clinical Outcomes, Mahmoud et al.4 address this question through a multicentre propensity-matched analysis comparing GLP-1 receptor agonists (GLP-1RAs) with bariatric surgery in adults with HCM and body mass index ≥30 kg/m2. After matching, 955 patients remained in each group, representing, to our knowledge, the first direct comparison of GLP-1 receptor agonists and bariatric surgery in patients with hypertrophic cardiomyopathy and obesity. Over 24 months, GLP-1RA therapy was associated with lower all-cause mortality, fewer heart failure hospitalizations, and a lower composite cardiovascular endpoint than bariatric surgery, despite a smaller reduction in body mass index. Arrhythmic events and cardiovascular symptoms were similar between groups.4
No takes yet. Share an insight, caveat, or question.
Boettger et al. (2026) conducted an editorial in Hypertrophic cardiomyopathy and obesity (n=1,910). GLP-1 receptor agonists vs. Bariatric surgery was evaluated on All-cause mortality, heart failure hospitalizations, and composite cardiovascular endpoint. Over 24 months, GLP-1RA therapy was associated with lower all-cause mortality and fewer heart failure hospitalizations than bariatric surgery in 1,910 adults with hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: